← Leaderboards
Brendan D Curti
Providence Portland Medical Center
$3,242,071
Attributed
$5,062,652
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,062,652 · 4
By mechanism
R01$4,374,360 · 2
R21$688,292 · 2
Top collaborators
- William L Redmond6 shared
- Marka Crittenden2 shared
Most similar at Providence Portland Medical Center
Same institution · by research overlap
- William L Redmond$2,939,722
- Marka Crittenden$2,669,247
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorImmunotherapyT-LymphocyteImmuneMalignant NeoplasmsMetastatic MelanomaCombined Modality TherapyPhenotypeImmune SystemNeoplastic CellT Memory CellMediatingMelanomaFlow CytometryT Cell ResponseClinical CarePhase I Clinical TrialsCell PhysiologyInnovationMonocytePathway InteractionsGalectin 3Cancer Cell
Grant awards (13)
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$1,205,769
R01 · FY2025 · CA · contact PI
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$571,136
R01 · FY2024 · CA · contact PI
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$582,888
R01 · FY2023 · CA · contact PI
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$593,078
R01 · FY2021 · CA · contact PI
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma$185,992
R21 · FY2016 · CA · contact PI
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma$153,038
R21 · FY2015 · CA · contact PI
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma$156,122
R21 · FY2014 · CA
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma$193,140
R21 · FY2013 · CA
Clinical Development of anti-OX40 and OX40L$276,599
R01 · FY2008 · CA · contact PI
Clinical Development of anti-OX40 and OX40L$276,600
R01 · FY2007 · CA · contact PI
Clinical Development of anti-OX40 and OX40L$284,860
R01 · FY2006 · CA · contact PI
Clinical Development of anti-OX40 and OX40L$291,715
R01 · FY2005 · CA
Clinical Development of anti-OX40 and OX40L$291,715
R01 · FY2004 · CA